About this Research Topic
Myeloproliferative neoplasms (MPNs) are chronic hematologic malignancies associated with burdensome symptoms, and potentially fatal complications including thrombosis, myelofibrosis, and acute leukemia. To improve symptoms, prevent complications, and prolong survival, the treatment landscape of MPNs is rapidly evolving with several newly approved drugs and investigational agents in the clinic trial pipeline. This issue highlights current practices and future considerations in the management of MPN patients for an audience of MPN patients and general hematology practitioners.
This issue will encompass MPN topics that will be presented at the 12th international MPN patient symposium of the Cancer Research & Treatment (CR&T) Fund, and will include the following topics:
- Challenges in diagnostic distinction of MPNs
- Managing ET in 2023
- Managing PV in 2023
- Managing PMF in 2023
- Drivers of Progression of MPNs
- The Microbiome in the MPNs
- Inflammation in MPNs
- Promising new drugs for MPN therapy
- Demystifying bone marrow transplant for MPNs.
Types of manuscripts:
- Review articles
- Systematic review and meta-analyses
- Original articles including retrospective studies, case series, or prospective studies.
This issue will encompass MPN topics that will be presented at the 12th international MPN patient symposium of the Cancer Research & Treatment (CR&T) Fund, and will include the following topics:
- Challenges in diagnostic distinction of MPNs
- Managing ET in 2023
- Managing PV in 2023
- Managing PMF in 2023
- Drivers of Progression of MPNs
- The Microbiome in the MPNs
- Inflammation in MPNs
- Promising new drugs for MPN therapy
- Demystifying bone marrow transplant for MPNs.
Types of manuscripts:
- Review articles
- Systematic review and meta-analyses
- Original articles including retrospective studies, case series, or prospective studies.
Keywords: Essential thrombocythemia (ET), Polycythemia vera (PV), Primary myelofibrosis (PMF), Interferon alfa (IFN), JAK inhibitors (JAKi), novel agents
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
